Incyte (INCY) Competitors $71.93 -0.54 (-0.75%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INCY vs. ALNY, BIIB, UTHR, NBIX, BMRN, EXAS, EXEL, RGEN, HALO, and MDGLShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Incyte vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Incyte (NASDAQ:INCY) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings. Do insiders and institutionals hold more shares of INCY or ALNY? 97.0% of Incyte shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 17.6% of Incyte shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer INCY or ALNY? Incyte received 85 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.62% of users gave Incyte an outperform vote. CompanyUnderperformOutperformIncyteOutperform Votes122372.62% Underperform Votes46127.38% Alnylam PharmaceuticalsOutperform Votes113876.17% Underperform Votes35623.83% Which has higher valuation and earnings, INCY or ALNY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncyte$3.70B3.75$597.60M$0.14513.82Alnylam Pharmaceuticals$1.83B17.37-$440.24M-$2.62-94.00 Does the media refer more to INCY or ALNY? In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 17 mentions for Incyte. Incyte's average media sentiment score of 0.94 beat Alnylam Pharmaceuticals' score of 0.76 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, INCY or ALNY? Incyte has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Is INCY or ALNY more profitable? Incyte has a net margin of 0.80% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets Incyte0.80% -0.63% -0.45% Alnylam Pharmaceuticals -15.86%N/A -8.38% Do analysts rate INCY or ALNY? Incyte currently has a consensus target price of $76.29, suggesting a potential upside of 6.07%. Alnylam Pharmaceuticals has a consensus target price of $298.61, suggesting a potential upside of 21.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incyte 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72 SummaryIncyte beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.86B$4.14B$5.21B$9.14BDividend YieldN/A1.82%5.13%4.02%P/E Ratio513.8252.2789.1817.36Price / Sales3.7544.711,240.0477.11Price / Cash28.9723.2643.7535.97Price / Book3.113.335.314.79Net Income$597.60M$139.50M$122.54M$225.00M7 Day Performance-0.61%-0.36%0.59%2.62%1 Month Performance4.49%-3.53%2.55%3.81%1 Year Performance16.98%18.90%25.29%20.10% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7782 of 5 stars$71.93-0.7%$76.29+6.1%+17.0%$13.86B$3.70B513.822,524Short Interest ↓ALNYAlnylam Pharmaceuticals4.4417 of 5 stars$261.49+9.9%$298.61+14.2%+33.8%$33.73B$2.09B-99.812,100Analyst RevisionBIIBBiogen4.7142 of 5 stars$149.49+0.5%$230.00+53.9%-43.8%$21.78B$9.61B13.508,720UTHRUnited Therapeutics4.92 of 5 stars$365.50+0.1%$378.36+3.5%+64.8%$16.32B$2.76B16.05980Positive NewsNBIXNeurocrine Biosciences4.9048 of 5 stars$142.68+1.3%$164.81+15.5%+4.3%$14.45B$2.24B38.251,200Insider TradeBMRNBioMarin Pharmaceutical4.9986 of 5 stars$66.97-0.6%$94.20+40.7%-33.3%$12.76B$2.75B40.103,401Options VolumeEXASExact Sciences4.797 of 5 stars$57.82+2.3%$72.94+26.1%-21.4%$10.70B$2.69B-49.426,600EXELExelixis4.6009 of 5 stars$35.35-1.9%$33.75-4.5%+61.0%$10.10B$2.08B22.661,310Analyst RevisionRGENRepligen3.7251 of 5 stars$158.35+2.3%$185.20+17.0%-9.8%$8.87B$639.92M-427.962,020HALOHalozyme Therapeutics4.6444 of 5 stars$54.38+3.0%$60.89+12.0%+60.5%$6.92B$947.36M18.01390Short Interest ↑MDGLMadrigal Pharmaceuticals4.5411 of 5 stars$299.25-11.7%$350.83+17.2%+29.7%$6.53B$76.81M-11.9390Insider TradeAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INCY) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
